Cited by 519Multiple Sclerosis Research StudiesMental Health Treatment and AccessCancer survivorship and care

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review

Open access
Marrie, Ruth Ann, Reingold, Stephen, Cohen, Jeffrey, Stuve, Olaf, Trojano, Maria, Sorensen, Per Soelberg, Cutter, Gary, Reider, Nadia·2015·Multiple Sclerosis Journal

Abstract

BACKGROUND: Psychiatric comorbidity is associated with lower quality of life, more fatigue, and reduced adherence to disease-modifying therapy in multiple sclerosis (MS). OBJECTIVES: The objectives of this review are to estimate the incidence and prevalence of selected comorbid psychiatric disorders in MS and evaluate the quality of included studies. METHODS: We searched the PubMed, PsychInfo, SCOPUS, and Web of Knowledge databases and reference lists of retrieved articles. Abstracts were screened for relevance by two independent reviewers, followed by full-text review. Data were abstracted by one reviewer, and verified by a second reviewer. Study quality was evaluated using a standardized tool. For population-based studies we assessed heterogeneity quantitatively using the I² statistic, and conducted meta-analyses. RESULTS: We included 118 studies in this review. Among population-based studies, the prevalence of anxiety was 21.9% (95% CI: 8.76%-35.0%), while it was 14.8% for alcohol abuse, 5.83% for bipolar disorder, 23.7% (95% CI: 17.4%-30.0%) for depression, 2.5% for substance abuse, and 4.3% (95% CI: 0%-10.3%) for psychosis. CONCLUSION: This review confirms that psychiatric comorbidity, particularly depression and anxiety, is common in MS. However, the incidence of psychiatric comorbidity remains understudied. Future comparisons across studies would be enhanced by developing a consistent approach to measuring psychiatric comorbidity, and reporting of age-, sex-, and ethnicity-specific estimates.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1352458514564487

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A comprehensive systematic review of 118 studies found psychiatric comorbidities in MS were common; prevalence of diagnosed anxiety and depression were estimated at 21.9 and 23.7%, respectively.

    “A comprehensive systematic review of 118 studies on psychiatric comorbidities in MS found that psychiatric comorbidities were common; in particular, the prevalence of diagnosed anxiety and depression were estimated at 21.9 and 23.7%, respectively [53].”

    From Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap (2022) · cites this paper as [53]

    The Abstract Results report 118 studies and prevalence estimates of 21.9% for anxiety and 23.7% for depression among population-based studies; the Discussion says psychiatric comorbidity is common in MS. However, the Results (Psychiatric disorders) show that these estimates combine studies using diagnoses with studies using symptom questionnaires. They are not estimates specifically of diagnosed anxiety and depression. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • MS patients show increased levels of anxiety and depression compared to healthy participants, and these conditions affect more than 20% of patients.

    “MS patients show increased levels of anxiety and depression compared to healthy participants, and these conditions affect more than 20% of patients [8,21,22,23].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. 10.1176/jnp.2010.22.1.63 · DOI
  2. 10.1017/s0317167100034065 · DOI

Cited by

Sorted by citations

Authors
Marrie, R. A., Reingold, S., Cohen, J., Stuve, O., Trojano, M., Sorensen, P. S., Cutter, G., & Reider, N.
Affiliations
  • University of Manitoba (CA)
  • Scientific and Clinical Review Associates, LLC, USA
  • Cleveland Clinic (US)
  • Department of Neurology and Neurotherapeutics, University of Texas Southwestern, USA
  • Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Italy
  • Department of Neurology, Copenhagen University Hospital Rigshospitalet, Denmark
  • University of Alabama at Birmingham (US)
Corresponding author
Marrie, Ruth Ann
Venue
Multiple Sclerosis Journal
Published
2015-01-12
Volume
21
Issue
3
Pages
305-317
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
OpenAlex
W2105913548
Cited by
519
References
136
Citations by year
2026: 42 · 2025: 31 · 2024: 45 · 2023: 46 · 2022: 52 · 2021: 68 · 2020: 48 · 2019: 38 · 2018: 43 · 2017: 47 · 2016: 43 · 2015: 16
FWCI
7.28
Type
journal article
Language
en
Open access
Locations
  • Multiple Sclerosis Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Funders
  • U.S. Department of Defense
  • National Multiple Sclerosis Society
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Gilead Sciences
  • Biogen
  • Teva Pharmaceutical Industries
  • Cleveland Clinic
  • Multiple Sclerosis Society of Canada
  • Multiple Sclerosis Society
  • MedDay Pharmaceuticals
  • National Institutes of Health
  • Genentech
  • EMD Serono
  • National Heart, Lung, and Blood Institute
  • National Institute of Neurological Disorders and Stroke
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
multiple sclerosis, psychiatric comorbidity, depression, anxiety, alcohol abuse, bipolar disorder, substance abuse, psychosis, incidence, prevalence, quality of life, fatigue
MeSH terms
Mental Disorders, Humans, Multiple Sclerosis, Comorbidity, Incidence, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review